FDA clears Roche and Eli Lilly Alzheimer's blood test
The FDA cleared Roche and Eli Lilly's Elecsys pTau217 blood test to help identify signs of Alzheimer's disease in people age 55 and older with cognitive decline. It is the fourth Alzheimer's blood test to receive FDA clearance in less than two years. Labcorp and Quest Diagnostics plan to offer the test through their laboratory networks.
9
Divergence score
2 outlets covered it, splitting into 2 framing camps across 2 bias groups.
2 camps
2 bias groups
Market signalBETA
The spectrum · how 2 outlets placed this story
LeftCenterRight
CNN
The Hill
Supportive of action
Neutral
Dismissive
Critical
Alarmist
International angle
Widest split · the two outlets furthest apart, and who published first
First to report
- CNNfirst
- The Hill+7.9 h
By each outlet's earliest publish time in this story. Feeds that index slowly can appear later than they printed.
The split, in one line
Both outlets report the same FDA clearance with minimal divergence; CNN provides extensive clinical context on limitations and false positives while The Hill briefly notes it as the fourth blood test approved.
How each outlet covered it
Lightly covered so far
Too few outlets to map a left-right split. Here is each take as it stands.
Sparse coverage · 2 outlets
“FDA approves new blood test for Alzheimer's disease”
“Roche, Eli Lilly's Alzheimer's blood test gets FDA clearance”
4 tracked claims across 2 outlets
Fact ledger
All4Claimed2Corroborated2
1/2
Claimed
Labcorp and Quest Diagnostics plan to offer the test through their laboratory networks.
Corroborated
Disputed
3 more tracked claimsSign up free to see the full ledger